LIVNLivaNova PLC

Ticker: LIVN | Current Price: $93.13 | Today's Change: +16.56%

---

What Happened

LivaNova PLC filed an 8-K with the SEC on November 4, 2026 (Items 2.02 and 9.01), disclosing its results for the second quarter of fiscal year 2026. Revenue from contracts with customers (excluding assessed tax) came in at $669.4 million for Q2 FY2026. Despite a positive operating income of $102.8 million, the company reported a net loss of $300.2 million, translating to a loss per share — both basic and diluted — of $5.51.

---

Why It Matters

The wide gap between operating income and net income is the most striking feature of this filing. LivaNova generated over $100 million in operating profit during the quarter, yet the bottom line swung to a net loss of more than $300 million — a gap of roughly $403 million. This strongly implies that significant charges below the operating line, such as impairments, tax provisions, legal settlements, or financing costs, drove the headline loss. Investors will need to scrutinize the full financial statements and footnotes (filed as an exhibit under Item 9.01) to identify the precise source of that drag. The stock's sharp 16.56% gain on the day suggests the market may have anticipated a worse outcome, or that the underlying operational performance — solid operating income — provided some reassurance.

---

Analysis

The numbers here tell two very different stories at once. On the operational side, $669.4 million in quarterly revenue accompanied by $102.8 million in operating income indicates that LivaNova's core business — spanning cardiac surgery, neuromodulation, and related segments — is generating meaningful cash-flow-level profits from its operations. That is not trivial.

The net loss of $300.2 million, however, demands explanation. Until the specific below-the-line charges are identified and evaluated for recurrence, investors cannot treat this as a clean quarter. If the loss is driven by a one-time, non-cash charge (an asset impairment, for example), the market's positive reaction becomes more logical. If it reflects ongoing cash outflows — such as litigation settlements, elevated interest expense, or tax liabilities — the picture is more complicated.

Key things to watch:

• The nature and recurrence of below-the-line charges driving the $403M wedge between operating income and net income
• Whether Q2 revenue of $669.4M represents sequential or year-over-year growth relative to prior periods
• Management's guidance commentary, if any, included with the 8-K exhibit package
• Any updated outlook on litigation or financing arrangements that may have contributed to the loss

The outsized stock move of +16.56% on this filing date reflects how negatively the market had been positioned heading into this print — and the operational resilience embedded in the top-line and operating income figures appears to have provided material relief.

---

Disclaimer

This report is provided for informational and journalistic purposes only. It is based solely on data extracted from LivaNova PLC's SEC filing (Form 8-K, filed November 4, 2026) and publicly available market data. It does not constitute investment advice, a solicitation to buy or sell any security, or an equity research recommendation of any kind. Readers should conduct their own due diligence and consult a qualified financial professional before making any investment decisions.

Source

Filed with the SEC on 2026-11-04. Read the original filing on EDGAR: https://www.sec.gov/Archives/edgar/data/1639691/000163969126000111/livn-20261104.htm